Head-to-head evidence
APG990 vs IBI356
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: OX40L · full Atopic Dermatitis pipeline
APG990
Developed by Apogee Therapeutics and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
IBI356
Developed by Innovent Biologics
NCT06193434 · Phase 1 · completed
This is a randomized, blinded study with both a placebo and an active comparator (dupilumab), which is a sound design, but its primary measure is safety monitoring rather than a skin-disease severity outcome, and no results have been posted yet.
Next expected readout: June 2027 · NCT07330934 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: APG990's landscape · IBI356's landscape